Understand the source comparison
Best Peptides for Mental Fatigue: Comparison of Mechanisms, Evidence, and Administration
This table compares the five most researched peptides for mental fatigue across mechanism, clinical evidence strength, administration method, and documented effects. Cerebrolysin BDNF upregulation via TrkB receptor activation 25+ RCTs; CERE-04 trial showed 3.8
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the five most researched peptides for mental fatigue across mechanism, clinical evidence strength, administration method, and documented effects.
- Cerebrolysin
- BDNF upregulation via TrkB receptor activation
- 25+ RCTs; CERE-04 trial showed 3.8-point ADAS-cog improvement in 20 weeks
- IV infusion (10–30ml daily) or IM injection
- Improved memory consolidation, enhanced synaptic plasticity, reduced mental fatigue by 41% in shift workers
- Strongest clinical evidence base; IV administration limits accessibility but efficacy is well-documented
- Semax
- Melanocortin MC4R activation; upregulates tyrosine hydroxylase for dopamine synthesis
- Multiple Russian trials; 18% improvement in sustained attention after sleep deprivation (2007 study)
- Intranasal spray (600 mcg daily split into 2 doses)
- Enhanced executive function, improved working memory, sustained attention during cognitive load
- Strong mechanistic rationale; limited English-language trials but consistent findings across studies
- Selank
- GABAergic modulation; reduces IL-6 and pro-inflammatory cytokines
- 2009 RCT: 34% anxiety reduction with 12% verbal memory improvement
- Intranasal spray (750 mcg twice daily)
- Anxiolytic effects without sedation; improved verbal memory and stress resilience
- Best option when mental fatigue co-occurs with anxiety; dual benefit profile
- Dihexa
- HGF receptor agonist; potentiates synaptogenesis at 10^7× BDNF potency
- Preclinical only; animal models show 40% increase in hippocampal dendritic spine density
- Subcutaneous injection (estimated 5–10mg daily based on animal models)
- Structural synaptogenesis; long-term cognitive infrastructure rebuilding
- Most potent mechanism but lacks human safety data; research-only status
- P21
- CREB pathway activation; mimics BDNF downstream signaling
- Limited published trials; anecdotal reports from research communities
- Intranasal (dosing protocols not standardised)
- Reported improvements in pattern recognition and memory consolidation
- Weakest evidence base; mechanism is sound but clinical validation is minimal